The tweet was deleted by the author.
But we saved everything 🙂.
Madrigal Pharmaceuticals states that the inaugural SOLAR Conference is approaching.
The company says it anticipates discussing the complexities of liver disease and ways to improve the lives of people living with MASH. Madrigal Pharmaceuticals adds that the event will take place in San Juan.
View post on X Loading...
At $511.61, MDGL trades above the MA-20 ($493.72), MA-50 ($509.56), and MA-200 ($493.78), indicating a bullish trend structure across short and long-term averages. The Ichimoku Kijun on D1 is at $496.22, acting as immediate support with near-term support at the Kijun ($496.22) and key support at MA-200 ($493.78), while near-term resistance is the MA-50 ($509.56) and key resistance is the next weekly high at $516.99.
Momentum signals on D1 are mixed. MACD signals a strong sell, while ADX at 13.64 is neutral, reflecting weak trend strength. RSI (55.92) and CCI (71.36) both support continued buying but Stoch RSI and BBP show clear overbought conditions, warning of short-term buyer exhaustion. BBP’s high positive value signals buyer dominance intraday, but Awesome Oscillator is neutral and divergence among key indicators is evident. MDGL has risen $5.86 (1.24%) over the past week and is currently trading at $511.61, up from last week’s close of $505.75 and positioned at the very top of the weekly range. Weekly volatility stands at 6.06%. The weekly tone reflects ongoing upward momentum with price pressing near resistance after a strong run.
For the coming week, the expected price range for MDGL is $508 to $528, keeping the forecast corridor just above the current level while remaining well between the 52-week low ($277.64) and high ($615.00). Based on W1 readings—MA-50, RSI, and MACD all show Buy or Strong Buy—there is a very high probability (more than 80%) of an upward move, while the likelihood of a decline is very low. The baseline scenario calls for sideways consolidation between $508 and $518. A bullish scenario would see a break above $518 resistance, targeting the $528 zone. In a bearish turn, a drop below the $508 support area could trigger profit taking toward $496. Traders should be alert to short-term corrections if overbought pressures intensify.
Earlier, analysts highlighted a balanced but cautious outlook for Madrigal Pharmaceuticals with price action expected to consolidate amid mixed technical signals. In light of ongoing developments, traders should monitor for a decisive shift in momentum that could define the prevailing scenario for the next phase.